Definitive Contract HHSN261201000119C

Ended Awarded Last action

Contract number
HHSN261201000119C
Awardee
Awarding agency
Obligated
$999,326

Award facts

Opportunity
Contract value 100% obligated
$999,325.75 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Buffalo, NY 14203, USA
Research
SBIR Program Phase II Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out 7 · Modified to deobligate all remaining funds and administratively close the contract -$316
Other Administrative Action 6 $0
Other Administrative Action 5 $0
Other Administrative Action 4 · Platelet-based nanoparticle therapy for prostate cancer $0
Other Administrative Action 3 $0
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $999,642

Quick answers

Who was awarded contract HHSN261201000119C?

HHSN261201000119C was awarded to Androbiosys, Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2010.

How much is contract HHSN261201000119C worth?

The government has obligated $999,326 on HHSN261201000119C.

Was contract HHSN261201000119C competed?

The extent of competition for HHSN261201000119C was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award